Advertisement

Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models

Published:October 19, 2014DOI:https://doi.org/10.1016/j.ajog.2014.10.026

      Objective

      There is increasing preclinical evidence indicating that metformin, a medication commonly used for type 2 diabetes mellitus, may protect against cancer. Motivated by this emerging evidence we asked 2 questions: (1) can metformin prevent ovarian cancer growth by altering metabolism and (2) will metformin increase sensitivity to chemotherapy.

      Study Design

      The effect of metformin in ovarian cancer was tested in vitro and with 2 different mouse models. In vitro, cell lines (n = 6) were treated with metformin (10-40 mmol/L) or phosphate-buffered saline solution and cellular proliferation and metabolic alterations (adenosine monophosphate–activated protein kinase activity, glycolysis, and lipid synthesis) were compared between the 2 groups. In mouse models, a prevention study was performed by treating mice with metformin (250 mg/kg/d intraperitoneally) or placebo for 2 weeks followed by intraperitoneal injection of the SKOV3ip1 human ovarian cancer cell line, and the mean number of tumor implants in each treatment group was compared. In a treatment study, the LSL-K-rasG12D/+/PTENfloxP/floxP genetic mouse model of ovarian cancer was used. Mice were treated with placebo, paclitaxel (3 mg/kg/wk intraperitoneally for 7 weeks), metformin (100 mg/kg/d in water for 7 weeks), or paclitaxel plus metformin, and tumor volume was compared among treatment groups.

      Results

      In vitro, metformin decreased proliferation of ovarian cancer cell lines and induced cell cycle arrest, but not apoptosis. Further analysis showed that metformin altered several aspects of metabolism including adenosine monophosphate–activated protein kinase activity, glycolysis, and lipid synthesis. In the prevention mouse model, mice that were pretreated with metformin had 60% fewer tumor implants compared with controls (P < .005). In the treatment study, mice that were treated with paclitaxel plus metformin had a 60% reduction in tumor weight compared with controls (P = .02), which is a level of tumor reduction greater than that resulting from either paclitaxel or metformin alone.

      Conclusion

      Based on these results, we conclude that metformin alters metabolism in ovarian cancer cells, prevents tumor growth, and increases sensitivity to chemotherapy in vitro and in mouse models. These preclinical findings suggest that metformin warrants further investigation for use as an ovarian cancer therapeutic.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Adams C.P.
        • Brantner V.V.
        Estimating the cost of new drug development: Is it really 802 million dollars?.
        Health Aff (Millwood). 2006; 25: 420-428
        • Chong C.R.
        • Sullivan D.J.
        New uses for old drugs.
        Nature. 2007; 448: 645-646
        • Bowker S.L.
        • Majumdar S.R.
        • Veugelers P.
        • Johnson J.A.
        Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
        Diabetes Care. 2006; 29: 254-258
        • Evans J.M.M.
        • Donnelly L.A.
        • Emslie-Smith A.M.
        • Alessi D.R.
        • Morris A.D.
        Metformin and reduced risk of cancer in diabetic patients.
        Br Med J. 2005; 530: 1304-1305
        • Libby G.
        • Donnelly L.A.
        • Donnan P.T.
        • Alessi D.R.
        • Morris A.D.
        • Evans J.M.M.
        New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes.
        Diabetes Care. 2009; 32: 1620-1625
        • Landman G.W.
        • Kleefstra N.
        • van Hateren K.J.J.
        • Groenier K.H.
        • Gans R.O.
        • Bilo H.J.
        Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC -16.
        Diabetes Care. 2010; 33: 322-326
        • Memmott R.M.
        • Mercado J.R.
        • Maier C.R.
        • Kawabata S.
        • Fox S.D.
        • Dennis P.A.
        Metformin prevents tobacco carcinogen- induced lung tumorigenesis.
        Cancer Prev Res. 2010; 3: 1066-1076
        • Buzzai M.
        • Jones R.G.
        • Amaravadi R.K.
        • et al.
        Systemic treatment with the anti-diabetic drug metformin selectively impairs p53-deficient tumor cell growth.
        Cancer Res. 2007; 67: 6745-6752
        • Cufi S.
        • Corominas-Faja B.
        • Vazquez-Martin A.
        • et al.
        Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
        Oncotarget. 2012; 3: 395-398
        • Sahra I.B.
        • Laurent K.
        • Loubat A.
        • et al.
        The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
        Oncogene. 2008; 27: 3576-3586
        • Zhou G.
        • Myers R.
        • Li Y.
        • et al.
        Role of AMP-activated protein kinase in mechanism of metformin action.
        J Clin Invest. 2001; 108: 1167-1174
        • Goodwin P.J.
        • Stambolic V.
        • Lemieux J.
        • et al.
        Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents.
        Breast Cancer Res Treat. 2011; 126: 215-220
        • Higurashi T.
        • Takahasi H.
        • Endo H.
        • et al.
        Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial.
        BMC Cancer. 2012; 12: 1-7
        • Romero I.L.
        • McCormick A.
        • McEwen K.A.
        • et al.
        Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity.
        Obstet Gynecol. 2012; 119: 61-67
        • Kumar S.
        • Meuter A.
        • Thapa P.
        • et al.
        Metformin intake is associated with better survival in ovarian cancer: a case-control study.
        Cancer. 2013; 119: 555-562
        • Bakhru A.
        • Buckanovich R.J.
        • Griggs J.J.
        The impact of diabetes on survival in women with ovarian cancer.
        Gynecol Oncol. 2011; 121: 106-111
        • Romero I.L.
        • Gordon I.
        • Jagadeeswaran S.
        • et al.
        Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice.
        Cancer Prev Res. 2009; 2: 792-799
        • Kenny H.A.
        • Leonhardt P.
        • Ladanyi A.
        • et al.
        Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.
        Clin Cancer Res. 2011; 17: 459-471
        • Sawada K.
        • Radjabi A.R.
        • Shinomiya N.
        • et al.
        c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.
        Cancer Res. 2007; 67: 1670-1680
        • Sawada K.
        • Mitra A.K.
        • Radjabi A.R.
        • et al.
        Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target.
        Cancer Res. 2008; 68: 2329-2339
        • Shell S.
        • Park S.M.
        • Radjabi A.R.
        • et al.
        Let-7 expression defines two differentiation stages of cancer.
        Proc Natl Acad Sci U S A. 2007; 104: 11400-11405
        • Romero I.L.
        • Lee W.
        • Mitra A.K.
        • et al.
        The effects of 17ß-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis.
        Gynecol Oncol. 2012; 124: 134-141
        • Zillhardt M.
        • Christensen J.
        • Lengyel E.
        An orally available small molecule inhibitor of c-Met, PF-2341066, reduces tumor burden in a pre-clinical model of ovarian cancer metastasis.
        Neoplasia. 2010; 12: 1-10
        • Dinulescu D.
        • Ince T.A.
        • Quade B.
        • Shafer S.
        • Crowley D.
        • Jacks T.
        Role of K-ras and PTEN in the development of mouse models of endometriosis and endometrioid ovarian cancer.
        Nat Med. 2005; 11: 63-70
        • Kilkenny C.
        • Browne W.J.
        • Cuthill I.C.
        • Emerson M.
        • Altman D.G.
        Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research.
        PLoS Biol. 2010; 8: 1-5
        • Memmott R.M.
        • Mercado J.R.
        • Maier C.R.
        • Kawabata S.
        • Fox S.D.
        • Dennis P.A.
        Metformin prevents tobacco carcinogen-induced lung tumorigenesis.
        Cancer Prev Res (Phila). 2010; 3: 1066-1076
        • Christensen M.M.
        • Brasch-Andersen C.
        • Green H.
        • et al.
        The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c.
        Pharmacogenet Genomics. 2011; 21: 837-850
        • Hardie D.G.
        AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy.
        Nature Rev. 2007; 8: 774-785
        • Swinnen J.V.
        • Brusselmans K.
        • Verhoeven G.
        Increased lipogenesis in cancer cells: new players, novel targets.
        Curr Opin Clin Nutr Metab Care. 2006; 9: 358-365
        • Nieman K.M.
        • Kenny H.A.
        • Penicka C.V.
        • et al.
        Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth.
        Nat Med. 2011; 17: 1498-1503
        • Clarke R.
        Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models.
        Breast Cancer Res Treat. 1997; 46: 255-278
        • Rattan R.
        • Graham R.P.
        • Maguire J.L.
        • Giri S.
        • Shridhar V.
        Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo.
        Neoplasia. 2011; 13: 483-491
        • Rattan R.
        • Giri S.
        • Hartmann L.C.
        • Shridhar V.
        Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner.
        J Cell Mol Med. 2011; 15: 166-178
        • Gotlieb W.H.
        • Saumet J.
        • Beauchamp M.C.
        • et al.
        In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.
        Gynecol Oncol. 2008; 110: 246-250
        • Song J.
        • Ren P.
        • Zhang L.
        • Wang X.
        • Li C.
        • Shen Y.H.
        Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4.
        Biochem Biophys Res Commun. 2010; 393: 89-94
        • Nieman K.M.
        • Romero I.L.
        • Van Houten B.
        • Lengyel E.
        Adipocyte tissue and adipocytes support tumorigenesis and metastasis.
        Biochim Biophys Acta. 2013; 1831: 1533-1541
        • Matei D.
        • Emerson R.E.
        • Lai Y.C.
        • et al.
        Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer.
        Oncogene. 2006; 25: 2060-2069
        • Ferrandina G.
        • Martinelli E.
        • Petrillo M.
        • et al.
        Prognostic role of the recepteur d'origine nantais (RON) expression in ovarian cancer patients.
        Gynecol Oncol. 2008; 111: 237-243
        • Lafky J.M.
        • Wilken J.A.
        • Baron A.T.
        • Maihle N.J.
        Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.
        Biochim Biophys Acta. 2008; 1785: 232-265
        • Klempner S.J.
        • Myers A.P.
        • Mills G.B.
        • Westin S.N.
        Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
        Expert Opin Pharmacother. 2013; 14: 2171-2182
        • Martin-Castillo B.
        • Vazquez-Martin A.
        • Oliveras-Ferraros C.
        • Menendez J.A.
        Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena.
        Cell Cycle. 2010; 9: 1057-1064
        • Ozols R.F.
        • Bundy B.
        • Greer B.E.
        • et al.
        Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
        J Clin Oncol. 2003; 21: 3194-3200
        • Erices R.
        • Bravo M.L.
        • Gonzalez P.
        • et al.
        Metformin, at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells.
        Reprod Sci. 2013; 20: 1433-1446
        • Jiralerspong S.
        • Palla S.L.
        • Giordano S.H.
        • et al.
        Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
        J Clin Oncol. 2009; 27: 3297-3302
        • Kisfalvi K.
        • Moro A.
        • Sinnett-Smith J.
        • Eibl G.
        • Rozengurt E.
        Metformin inhibits the growth of human pancreatic cancer xenografts.
        Pancreas. 2013; 42: 781-785
        • Hirsch H.A.
        • Iliopoulos D.
        • Struhl K.
        Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth.
        Proc Natl Acad Sci U S A. 2013; 110: 972-977
        • Bao B.
        • Wang Z.
        • Ali S.
        • et al.
        Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.
        Cancer Prev Res (Phila). 2012; 5: 355-364
      1. National Institutes of health. Clinical Trials home page. Available at: http://clinicaltrials.gov/ . Accessed Sept. 1, 2014.